Articles tagged with Type 1 Diabetes
A 30-year study published in the journal Diabetes found that type 1 diabetics showed improved mortality and morbidity rates for certain complications, but cardiovascular disease rates remained unchanged. The study suggests that focusing solely on blood-glucose control is insufficient to prevent long-term complications of type 1 diabetes.
Researchers found a synergistic combination of a low-dose CD3 antibody and proinsulin peptide to reverse recent-onset type 1 diabetes in mice, promoting pancreatic beta cell regeneration. This approach may hold great potential for the treatment of individuals with recent-onset type 1 diabetes.
Researchers develop a combination therapy that reverses recent-onset type 1 diabetes in mice by inducing regulatory T cells to shield insulin-producing cells from autoimmune destruction. The therapy, which combines an oral and intranasal treatment, shows greater efficacy than individual treatments alone.
Researchers at La Jolla Institute for Immunology have made a major finding on a potential cure for type 1 diabetes by combining two therapies, producing better efficacy and longer-lasting results in preclinical trials. The combination therapy is being planned to begin human clinical trials later this year.
Researchers found that new islet cells are host-derived, not from donor spleen cells, and that beta-cell growth was permitted when autoimmunity was suppressed. The study suggests that CFA alone may be effective in treating type 1 diabetes without the need for donor spleen cells.
A University of Calgary bioengineering team has successfully grown insulin-producing cells in a lab, which could lead to the production of human tissue for transplantation. The breakthrough brings the team one step closer to addressing the serious condition that requires multiple daily insulin injections.
A study published in Diabetes Care found that tight blood glucose control can reduce the risk of nerve problems and foot amputations in diabetics. The study involved 1,441 people with Type 1 diabetes who had controlled their blood sugar tightly for at least five years.
A worldwide study is screening 220,800 healthy babies for genes that increase risk of developing type 1 diabetes. The researchers aim to identify environmental triggers that determine the risks for the disease.
Research suggests that obesity is linked to accelerated type I diabetes onset in patients with severely compromised pancreatic beta-cell function. Low birth weight also appears to be a contributing factor, with advanced age at diagnosis observed as birth weight decreased.
Researchers detected lower gray matter density in brains of patients with Type 1 diabetes, associated with poorer glycemic control and depression. The study opens up new approaches to understanding the central nervous system in diabetes.
A detailed study of the Major Histocompatibility Complex (MHC) region reveals a region of stability that may have provided protection against infection and disease. The study found over 300 amino acid changing variants, strong candidates for functional studies to understand the role of variation in MHC-associated disease.
Research shows that tight glucose control significantly reduces heart disease and damage to the eyes, nerves, and kidneys in people with type 1 diabetes. The study found a 42% lower risk of cardiovascular events and a 58% lower risk of serious events like heart attacks or strokes.
A long-term study of patients with type 1 diabetes found that early and aggressive treatment, including insulin pumps and lifestyle interventions, significantly lowered the risk of serious cardiovascular events. This approach was associated with a 58% reduction in cardiovascular risks compared to conventional blood glucose control.
Research by Corbett et al. reveals that islet cells are susceptible to necrosis when exposed to interleukin-1, a cytokine that triggers b-cell release of HMGB1. This process contributes to the development of diabetes.
Researchers developed a new approach to predict type 1 diabetes risk by combining older and newer methods, identifying a specific protein marker associated with rapid progression. The study found that individuals positive for this marker have an 80% risk of developing the disease after just 6.7 years.
The study found that the overall incidence of ESRD among type 1 diabetes patients is lower than previously reported. Patients diagnosed at a younger age and in later years had a smaller risk of developing ESRD. The risk of death increased with age, but patients diagnosed in the 1970s had a significantly lower risk of dying.
A new method to create a reversibly immortalized beta-cell line offers significant progress in developing an effective treatment for type 1 diabetes. The breakthrough, achieved by manipulating human beta-cells, has successfully controlled blood sugar levels in diabetic mice for over 30 weeks.
A new imaging technology has shown promise in detecting pancreatic inflammation in type 1 diabetes, allowing for early prediction of disease progression and response to treatment. The technique uses magnetic nanoparticles and MRI to identify inflamed pancreatic islets, potentially reducing the need for invasive biopsies.
Researchers developed a novel MRI strategy to visualize inflammatory lesions in the pancreas that cause type-1 diabetes. This new approach provides preclinical data on mouse models, guiding the application of an in vivo MRI technique to patients with autoimmune diabetes.
A new clinical trial has shown that the oral treatment RBX may reduce the risk of moderate vision loss caused by macular edema in patients with type 1 or type 2 diabetes. The study, led by Joslin Diabetes Center, evaluated the safety and effect of RBX on retinopathy progression and visual loss.
A new study found that diabetic patients are at higher risk for developing respiratory tract, skin and mucous membrane, and urinary tract infections. The odds were significantly higher for both type 1 and type 2 diabetic patients compared to non-diabetic controls.
Researchers found teen-age boys with Type 1 diabetes have significantly higher intima-media thickness than those without the disease, indicating greater atherosclerosis progression. Smoking and poor glucose control are key risk factors for cardiovascular disease in this population.
A North Carolina woman has successfully undergone an experimental islet cell transplant procedure, allowing her to become insulin-free. The procedure, performed at Carolinas Medical Center, is still in its early stages but holds promise for millions of people with Type 1 diabetes.
A study found that introducing gluten-containing foods to infants at 1-3 months old significantly increased the risk of developing celiac disease, compared to exposure between 4-6 months. The findings suggest that early exposure to gluten may trigger an immune response in genetically predisposed children.
Researchers at Joslin Diabetes Center have identified genetic regions involved in autoimmune diseases, including type 1 diabetes. The study found a chromosomal region where T-cells were given the green light to attack beta cells, leading to insulitis and later type 1 diabetes.
Researchers at Northwell Health's Institute for Medical Research have identified a crucial gene in type 1 diabetes development, which triggers the immune system to attack and kill beta cells. Blocking this protein may halt the harmful process and allow remaining beta cells to produce insulin.
Researchers found that the MIF gene is crucial for the development of type 1 diabetes. Specially bred mice without the gene failed to develop diabetes compared to those with it. The finding provides proof of concept for blocking the formation of this protein as a promising approach to fighting diabetes.
Researchers successfully transplanted islets from a single donor pancreas into eight women with type 1 diabetes, achieving insulin independence and freedom from hypoglycemia. The trial resulted in superior glycemic control in four of five recipients with sustained insulin independence.
A study published in Diabetologia found that higher levels of protein adiponectin are associated with a lower risk of coronary artery disease (CAD), even independent of conventional risk factors. The study showed a remarkable 63% reduction in CAD risk for each 6.3 microgram per milliliter increase in serum adiponectin levels.
The Genetics of Kidneys in Diabetes (GoKinD) collection provides nearly 10,000 DNA and clinical data samples from adults with type 1 diabetes in the US and Canada. The resource aims to study genes linked to kidney disease and diabetes.
The study aims to identify genetic markers that can predict the onset of type 1 diabetes. The researchers plan to analyze the human genome, messenger RNA, and proteins to find reliable predictors of the disease, which may lead to new treatments and a potential cure.
A study by Joslin Diabetes Center found that youth ages 8-18 with type 1 diabetes were more likely to monitor their blood glucose levels when playing a guessing game on a wireless-equipped personal digital assistant. The study showed an increase in diabetes knowledge and fewer episodes of hyperglycemia among participants.
Researchers at Northwestern University are developing novel biomaterials and imaging techniques to improve the survival and function of transplanted islet cells in patients with type 1 diabetes. The grant will fund efforts to create microenvironments favorable for islet survival and function via controlled delivery of biological factors.
Researchers at Joslin Diabetes Center have developed a new imaging technology using magnetic resonance imaging to detect early signs of type 1 diabetes. The technology tracks miniscule magnetic nanoparticles leaking from the blood vessels of the pancreas, allowing for non-invasive monitoring of the disease's progression.
Researchers at Baylor College of Medicine have discovered a new gene associated with an increased risk of developing type 1 diabetes. SUMO-4 plays a key role in regulating the immune system and has been found to prolong the inflammatory response when mutated, leading to cell death and destruction of insulin-producing cells.
The study found that increasing PPAR-gamma activity in dendritic cells can activate NKT cells specifically, which may slow down the process of type 1 diabetes. Researchers believe that modulating CD1d expression and NKT cell activation could provide insight into how to combat autoimmunity.
Researchers found a natural mutation of the SUMO-4 gene, which regulates immune system activity, to be a major contributor to type 1 diabetes. The mutation increases the immune system's reactivity to environmental triggers, leading to an autoimmune response that attacks the patient's own tissue.
Researchers studied insulitis lesions in genetically engineered mice and discovered that inducible co-stimulator (ICOS) plays a crucial role in keeping insulitis respectful. Blocking ICOS disrupts the balance between T effector and regulatory cells, leading to diabetes progression.
Researchers discover a new strategy to combat type 1 diabetes by blocking the interaction of RAE-1 with its immune receptor, NKG2D. The treatment has shown complete effectiveness in preventing diabetes development in mice and promises potential as an effective human treatment.
Researchers at Rockefeller University have discovered that dendritic cells can stimulate the growth of suppressor T cells, which turn off the immune response and rescue islet cells from destruction. This breakthrough could lead to a prevention of Type 1 diabetes in humans.
Researchers found that natural killer cells are associated with destructive insulitis and beta cell destruction, suggesting a potential new target for halting or slowing disease progression. The study's findings have implications for understanding the complex interactions between immune cells and the development of type 1 diabetes.
A new protein form, liCTLA-4, found to inhibit T cell responses and reduce activation. Increased expression of liCTLA-4 in resistant mice strains suggests its role in preventing T cell-mediated autoimmune diseases like type 1 diabetes.
UVa researchers have identified a gene, Stat-4, that plays a key role in the development of type 1 diabetes. Disrupting this gene may help prevent the disease, and a new anti-inflammatory compound, Lisofylline (LSF), has shown promise in inhibiting its activation.
A synthetic compound called ISO-1 appears to work by blocking inflammation and protecting mice from developing type 1 diabetes. The researchers believe it could be developed into an oral drug that provides long-lasting protection for young people.
Researchers have successfully treated individuals with Type 1 diabetes using a single infusion of islet cells, with recipients maintaining insulin independence for over one to three years. The new treatment approach uses optimized recipient immunosuppression and a novel anti-CD3 monoclonal antibody.
Researchers develop gene therapy to enhance islet cell function and survival after transplantation. The technique uses a growth factor DNA to induce cell division, improving insulin production and glucose control in rat models. However, standard immunosuppression drug therapy may be harmful, inducing insulin resistance and diabetes.
A new study by the Society for Women's Health Research has found that spleen cells can rapidly regrow adult islet cells without embryonic stem cells. This breakthrough discovery opens up a new approach to treating Type 1 diabetes, which develops when the immune system attacks insulin-producing islet cells.
A study found that prenatal exposure to a diabetic environment from mothers with type 1 diabetes is associated with increased occurrence of impaired glucose tolerance and a defective insulin secretory response in adult offspring. This effect was observed independently of genetic predisposition to type 2 diabetes.
Researchers discovered that lisofylline treatment reduced the incidence of Type 1 diabetes in mice by 67%, indicating its potential to protect insulin-producing cells. The study published in Pancreas journal suggests that lisofylline may slow down or prevent the disease in people at high-risk.
A new study suggests that type 1 diabetics can develop insulin resistance, increasing their risk of heart disease. Insulin resistance occurs when the body fails to use insulin properly, leading to high blood sugar levels and a greater risk of cardiovascular events.
Sick Kids researchers discovered that nervous system autoimmunity attacks insulin-producing cells in the earliest stages of Type 1 diabetes. By modifying the attack on nervous tissue, they prevented subsequent diabetes in animal models, suggesting a critical role for early neuronal autoimmunity.
The international Type 1 Diabetes Genetics Consortium will collect and analyze genetic data from 2,500 families worldwide to identify genes contributing to the disease. The consortium aims to clarify the complex interaction between genetics and environment in type 1 diabetes.
Researchers found that increased nighttime systolic blood pressure is predictive of microalbuminuria and kidney disease in type 1 diabetes patients. The study suggests that this early warning sign may help prevent unnecessary therapies.
Researchers found strong relationships between nephropathy and insulin resistance throughout follow-up, unlike other risk factors such as blood pressure and blood fats. Lifestyle changes like proper diet, exercise, and smoking cessation may help people with type 1 diabetes avoid kidney disease.
Newborn diabetes screening benefits patients, medicine, and society by preventing complications, identifying at-risk individuals, and advancing research. Early detection enables targeted interventions to improve disease management, reduce hospitalizations, and lower medical costs.
Researchers have discovered a gene, Ian5, that appears to affect the function of the thymus and is linked to the development of type 1 diabetes in rats. The identification of this gene may also contribute to human type 1 diabetes and help researchers understand the underlying mechanisms of the disease.
A study of 200 type 1 diabetic patients found a significantly higher mortality rate among African Americans, due largely to acute complications. The results suggest an inadequacy in care for African Americans with type 1 diabetes, potentially linked to issues such as access to care and education.
Recent clinical trials found that low-dose insulin injections do not delay or prevent type 1 diabetes in high-risk individuals, contrary to earlier animal studies and pilot trials. However, the trials revealed valuable insights into immune and metabolic markers for assessing diabetes risk and identifying potential prevention strategies.
A new clinical trial has shown that a short-term use of a new drug can safely arrest the progression of Type 1 diabetes by targeting disease-causing T-cells. Patients who took the drug continued to produce their own insulin and needed less supplemental hormone, leading to improved metabolic control and reduced complications.
The new center will explore various initiatives toward insulin independence without long-term immunosuppression. Researchers will investigate less toxic drugs and test donor islets protected by a sheath-like membrane to reduce immune response.